GLMD

Eocene Ltd. (GLMD) | Rumor.io

Eocene

GLMD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,089

Bullish sentiment (50-day avg)72%

Price to earnings ratio0.02

Market capitalization3.9M

Earnings per share-14.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.3M

Social

What share of all stock conversation is about GLMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 19

Galmed Pharmaceuticals Ltd. ($GLMD) announced positive first-in-human proof-of-concept results for Colospan's intraoperative tissue assessment technology.
The company executed a 1-for-8 reverse stock split, effective August 19, 2026, which will reduce the estimated new tradable float to ~1.04 million shares.
Galmed has a low float and good news, with some investors expecting a potential price increase to $30-$50 per share.

Generated by AI

Sentiment

Of the messages about GLMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	80% +8.26	80.65% -1.43
Bearish	—	—	20% -8.26	19.35% +1.43

Bullish· Jun 8

Galmed Pharmaceuticals' acquisition of Colospan could transform the company into a GI-focused platform with real commercial potential.
The Colospan acquisition provides Galmed with FDA Breakthrough Device technology, a CE Mark approval in Europe, and a commercial launch planned for H2 2026.
The deal expands Galmed's market opportunity to a multi-billion dollar market, with a low market cap and potential for significant growth.

Bearish· Jun 8

The acquisition of Colospan by Galmed Pharmaceuticals may lead to increased competition in the $6 billion GI-focused market.
The company's stock price has failed to hold gains, with a notable decline after reaching 1.16.
Galmed Pharmaceuticals has experienced significant dilution, with 7.5 million shares issued, which may negatively impact investor confidence.

Generated by AI

Topics

Of the messages about GLMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	43.56%
Technical Analysis	—	—	0%	20.57%
Analysts	—	—	0%	17.89%
Controversies	—	—	0%	0.08%
Earnings	—	—	0%	0.16%
Macro	—	—	0%	17.73%

Earnings· Aug 1

GLMD is expected to report earnings on 08/02/2018 before market open.
The report will be for the fiscal quarter ending June 2018.
Earnings are expected to be released before the market open.

Analysts· May 15

Canaccord Genuity reiterates a buy rating for Galmed Pharmaceuticals ($GLMD) with a price target of $29.00.
HC Wainwright lowers the price target for Galmed Pharmaceuticals ($GLMD) to $29.00, maintaining a buy rating.
Raymond James maintains an outperform rating for Galmed Pharmaceuticals ($GLMD) with a price target of $20.00.

Announcements· Jul 16

Galmed Pharmaceuticals Ltd. (GLMD) unveiled a new cardiac-targeted LNP formulation of its SCD1 inhibitor Aramchol, designed to reach the heart instead of the liver, with the goal of advancing therapies for cardiac fibrosis.
The new formulation, developed in collaboration with Barcode Nanotech, is built using AI-enabled analysis and in vivo screening, and targets cardiac fibrosis, an area with no approved therapies that reverse it.
Galmed's announcement of the breakthrough development of the novel LNP cardiac targeted formulation of its SCD1 inhibitor, Aramchol, marks a potential expansion of the drug beyond its existing liver and gastrointestinal development programs.

Technical Analysis· Apr 9

$GLMD needs to break above the 1.20 resistance line to continue its upward trend.
$GLMD is forming a classic ascending triangle pattern, which could be a bullish sign for the stock.
$GLMD needs to break above the descending wedge and the VWAP to confirm its upward momentum.

Generated by AI

Community

Of the messages about GLMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	95%	61.77%
Newcomers	—	—	5%	38.23%

Regulars· Aug 19

The regulars are focused on the stock's potential to reach $30-$50, with one participant suggesting a price target of $30-$50 and another expressing optimism about the company's chances of achieving this target.
The recent good news about Galmed's drug, Aramchol, has the potential to support Xtandi's lifecycle management as key patents expire, with one participant citing a pre-clinical prostate cancer study that showed a 3–4x increase in cell death when combined with enzalutamide.
The regulars are concerned about the stock's low float and the lack of a significant price increase despite the recent good news, with one participant wondering how the stock can remain stagnant despite its potential.

Newcomers· Jul 16

Galmed Pharmaceuticals Ltd. (GLMD) has announced a new collaboration with Barcode Nanotech to develop a next-generation lipid nanoparticle (LNP) formulation of Aramchol, designed to redirect drug delivery from the liver to the heart.
The new LNP formulation of Aramchol targets cardiac fibrosis, a driver of 20.5% mortality rate in heart failure patients, and has the potential to expand the drug's market beyond its existing liver and gastrointestinal development programs.
GLMD stock has experienced significant price movements, with a 6.5% increase in the pre-market and a current price of $0.5445, with some analysts and traders speculating about the potential for further growth, including reaching the $1 level.

Generated by AI

News

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

21d agoYahoo Finance

Galmed Pharmaceuticals: Q2 Earnings Snapshot

27d agobarchart.com

Galmed completes feasibility study for colon tissue assessment tech

1mo agoInvesting.com

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Colospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), today announced the successful completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform. The technology represents Colospan's second platform, expanding the innovation pipeline beyond its lead product, CG-100, and reinforcing Galmed's strategy of building a diversified portfolio of technologies addressing significant unmet needs in colorec

1mo agoYahoo Finance

Galmed reports pre-clinical data on Aramchol-enzalutamide combo

1mo agoInvesting.com

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced significant results from a pre-clinical study of a combination of Aramchol and Xtandi® (enzalutamide) for prostatic cancer.

1mo agoYahoo Finance

Also Discussed

Investors talking about GLMD also mention

#	Name	Attention
1	Sonoma Pharmaceuticals Inc.SNOA	0%0
2	Odyssey Marine Exploration, Inc.OMEX	0%+0
3	Tenon Medical, Inc.TNON	0%new
4	Galectin Therapeutics Inc.GALT	0.01%+0.01
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	ICPT - Intercept Pharmaceuticals, Inc.	——
7	Kairos Pharma Ltd.KAPA	0%new
8	Clearmind Medicine Inc. Common SharesCMND	0%new
9	Oramed Pharmaceuticals Inc.ORMP	0%new
10	CN Energy Group Inc. Class A Ordinary SharesCNEY	0%0

Eocene Ltd.

Healthcare
Biotechnology

Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care. Its portfolio includes Aramchol, an oral therapeutic candidate being developed for liver-related indications, as well as medical device technologies designed to support postoperative colorectal treatment. Eocene Ltd. combines research, clinical development, and product commercialization activities across its healthcare platform, with operations centered in Ramat Gan, Israel. The company serves a niche role in the biotechnology market by pursuing therapies and technologies aimed at unmet needs in gastrointestinal and adjacent medical fields.

Website

Location

16 Abba Hillel Road

Ramat Gan, 5250608

Israel

Social

What share of all stock conversation is about GLMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 19

Galmed Pharmaceuticals Ltd. ($GLMD) announced positive first-in-human proof-of-concept results for Colospan's intraoperative tissue assessment technology.
The company executed a 1-for-8 reverse stock split, effective August 19, 2026, which will reduce the estimated new tradable float to ~1.04 million shares.
Galmed has a low float and good news, with some investors expecting a potential price increase to $30-$50 per share.

Generated by AI

Sentiment

Of the messages about GLMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	80% +8.26	80.65% -1.43
Bearish	—	—	20% -8.26	19.35% +1.43

Bullish· Jun 8

Galmed Pharmaceuticals' acquisition of Colospan could transform the company into a GI-focused platform with real commercial potential.
The Colospan acquisition provides Galmed with FDA Breakthrough Device technology, a CE Mark approval in Europe, and a commercial launch planned for H2 2026.
The deal expands Galmed's market opportunity to a multi-billion dollar market, with a low market cap and potential for significant growth.

Bearish· Jun 8

The acquisition of Colospan by Galmed Pharmaceuticals may lead to increased competition in the $6 billion GI-focused market.
The company's stock price has failed to hold gains, with a notable decline after reaching 1.16.
Galmed Pharmaceuticals has experienced significant dilution, with 7.5 million shares issued, which may negatively impact investor confidence.

Generated by AI

Topics

Of the messages about GLMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	43.56%
Technical Analysis	—	—	0%	20.57%
Analysts	—	—	0%	17.89%
Controversies	—	—	0%	0.08%
Earnings	—	—	0%	0.16%
Macro	—	—	0%	17.73%

Earnings· Aug 1

GLMD is expected to report earnings on 08/02/2018 before market open.
The report will be for the fiscal quarter ending June 2018.
Earnings are expected to be released before the market open.

Analysts· May 15

Canaccord Genuity reiterates a buy rating for Galmed Pharmaceuticals ($GLMD) with a price target of $29.00.
HC Wainwright lowers the price target for Galmed Pharmaceuticals ($GLMD) to $29.00, maintaining a buy rating.
Raymond James maintains an outperform rating for Galmed Pharmaceuticals ($GLMD) with a price target of $20.00.

Announcements· Jul 16

Galmed Pharmaceuticals Ltd. (GLMD) unveiled a new cardiac-targeted LNP formulation of its SCD1 inhibitor Aramchol, designed to reach the heart instead of the liver, with the goal of advancing therapies for cardiac fibrosis.
The new formulation, developed in collaboration with Barcode Nanotech, is built using AI-enabled analysis and in vivo screening, and targets cardiac fibrosis, an area with no approved therapies that reverse it.
Galmed's announcement of the breakthrough development of the novel LNP cardiac targeted formulation of its SCD1 inhibitor, Aramchol, marks a potential expansion of the drug beyond its existing liver and gastrointestinal development programs.

Technical Analysis· Apr 9

$GLMD needs to break above the 1.20 resistance line to continue its upward trend.
$GLMD is forming a classic ascending triangle pattern, which could be a bullish sign for the stock.
$GLMD needs to break above the descending wedge and the VWAP to confirm its upward momentum.

Generated by AI

Community

Of the messages about GLMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	95%	61.77%
Newcomers	—	—	5%	38.23%

Regulars· Aug 19

The regulars are focused on the stock's potential to reach $30-$50, with one participant suggesting a price target of $30-$50 and another expressing optimism about the company's chances of achieving this target.
The recent good news about Galmed's drug, Aramchol, has the potential to support Xtandi's lifecycle management as key patents expire, with one participant citing a pre-clinical prostate cancer study that showed a 3–4x increase in cell death when combined with enzalutamide.
The regulars are concerned about the stock's low float and the lack of a significant price increase despite the recent good news, with one participant wondering how the stock can remain stagnant despite its potential.

Newcomers· Jul 16

Galmed Pharmaceuticals Ltd. (GLMD) has announced a new collaboration with Barcode Nanotech to develop a next-generation lipid nanoparticle (LNP) formulation of Aramchol, designed to redirect drug delivery from the liver to the heart.
The new LNP formulation of Aramchol targets cardiac fibrosis, a driver of 20.5% mortality rate in heart failure patients, and has the potential to expand the drug's market beyond its existing liver and gastrointestinal development programs.
GLMD stock has experienced significant price movements, with a 6.5% increase in the pre-market and a current price of $0.5445, with some analysts and traders speculating about the potential for further growth, including reaching the $1 level.

Generated by AI

Eocene

Social

Aug 19

Bullish· Jun 8

Bearish· Jun 8

Earnings· Aug 1

Analysts· May 15

Announcements· Jul 16

Technical Analysis· Apr 9

Regulars· Aug 19

Newcomers· Jul 16

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed completes feasibility study for colon tissue assessment tech

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Galmed reports pre-clinical data on Aramchol-enzalutamide combo

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Also Discussed

Eocene Ltd.

Company Information

Location

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed completes feasibility study for colon tissue assessment tech

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Galmed reports pre-clinical data on Aramchol-enzalutamide combo

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Also Discussed

Social

Aug 19

Bullish· Jun 8

Bearish· Jun 8

Earnings· Aug 1

Analysts· May 15

Announcements· Jul 16

Technical Analysis· Apr 9

Regulars· Aug 19

Newcomers· Jul 16